Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00676832 · ClinicalTrials.gov registry record · Phase 2

Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis

A Phase 2 study, sponsored by Prometheus Laboratories.

Completed
Registry status
Phase 2
Development phase
190
Enrollment target

NCT00676832: Completed Phase 2 study, sponsored by Prometheus Laboratories.

NCT00676832 is a Phase 2 study that has completed, run by Prometheus Laboratories. The registered enrollment target is 190 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00676832, a Phase 2 study, has completed, sponsored by Prometheus Laboratories.

COMPLETED
Registry status
Phase 2
Development phase
190 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether COLAL-PRED is a safe and effective treatment for patients with moderate to severe ulcerative colitis.

Interventions

  • DRUG Placebo
  • DRUG COLAL-PRED

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2008-05
Est. Completion 2009-10
Phase Phase 2
Prometheus Laboratories

6 total trials

What the finished NCT00676832 record still lists

NCT00676832 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00676832 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00676832 about?

NCT00676832 is a clinical study titled "Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis". The purpose of this study is to determine whether COLAL-PRED is a safe and effective treatment for patients with moderate to severe ulcerative colitis.

What is the current status of trial NCT00676832?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2008-05. Estimated completion is 2009-10.

What interventions are being tested in trial NCT00676832?

The interventions under investigation include: Placebo (DRUG), COLAL-PRED (DRUG).

Who is sponsoring clinical trial NCT00676832?

This trial is sponsored by Prometheus Laboratories, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00676832's enrollment target sits among peer trials

190 353rd of 2000 higher than 1,646 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03257033 · 190 participants · Phase 3

    Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

  • NCT03642028 · 190 participants · Phase 4

    Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

  • NCT04015609 · 190 participants · NA

    Psychotherapy Intervention for Latinos With Advanced Cancer

  • NCT04284397 · 190 participants · Early Phase 1

    Identification of Critical Thermal Environments for Aged Adults

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00676832, the US trial registry maintained by the National Library of Medicine. NCT00676832 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.